Cliff Asness's WST Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 517,631 shares of West Pharmaceutical Services, Inc. (WST) worth $142.42 M, representing 0.07% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in WST, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 440,929 shares. Largest reduction occurred in Q2 2017, reducing 279,239 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's West Pharmaceutical Services (WST) Holding Value Over Time
Track share changes against reported price movement
Quarterly West Pharmaceutical Services (WST) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -28,248 | Reduce 5.17% | 517,631 | $275.14 |
| Q3 2025 | +440,929 | Add 420.13% | 545,879 | $261.87 |
| Q2 2025 | +100,569 | Add 2295.57% | 104,950 | $218.80 |
| Q1 2025 | -6,597 | Reduce 60.09% | 4,381 | $217.45 |
| Q4 2024 | -4,279 | Reduce 28.05% | 10,978 | $327.56 |
| Q3 2024 | -2,291 | Reduce 13.06% | 15,257 | $300.17 |
| Q2 2024 | -9,872 | Reduce 36.00% | 17,548 | $329.39 |
| Q1 2024 | -14,569 | Reduce 34.70% | 27,420 | $395.70 |
| Q4 2023 | -11,071 | Reduce 20.87% | 41,989 | $352.12 |
| Q3 2023 | +2,002 | Add 3.92% | 53,060 | $375.21 |
| Q2 2023 | +1,678 | Add 3.40% | 51,058 | $382.47 |
| Q1 2023 | -50,397 | Reduce 50.51% | 49,380 | $346.47 |
| Q4 2022 | +15,281 | Add 18.08% | 99,777 | $234.18 |
| Q3 2022 | -9,559 | Reduce 10.16% | 84,496 | $246.08 |
| Q2 2022 | -11,090 | Reduce 10.55% | 94,055 | $297.11 |
| Q1 2022 | -17,388 | Reduce 14.19% | 105,145 | $410.71 |
| Q4 2021 | -21,541 | Reduce 14.95% | 122,533 | $469.01 |
| Q3 2021 | +869 | Add 0.61% | 144,074 | $424.54 |
| Q2 2021 | -11,302 | Reduce 7.31% | 143,205 | $358.32 |
| Q1 2021 | -18,126 | Reduce 10.50% | 154,507 | $278.19 |
| Q4 2020 | +37,389 | Add 27.65% | 172,633 | $278.27 |
| Q3 2020 | +21,040 | Add 18.42% | 135,244 | $273.25 |
| Q2 2020 | -129,739 | Reduce 53.18% | 114,204 | $220.39 |
| Q1 2020 | +6,250 | Add 2.63% | 243,943 | $152.25 |
| Q4 2019 | -12,169 | Reduce 4.87% | 237,693 | $150.33 |
| Q3 2019 | +24,462 | Add 10.85% | 249,862 | $141.82 |
| Q2 2019 | +115,145 | Add 104.44% | 225,400 | $125.15 |
| Q1 2019 | +44,258 | Add 67.06% | 110,255 | $110.20 |
| Q4 2018 | +38,621 | Add 141.08% | 65,997 | $98.03 |
| Q3 2018 | +16,251 | Add 146.08% | 27,376 | $123.50 |
| Q2 2018 | +2 | Add 0.02% | 11,125 | $99.33 |
| Q1 2018 | -59,261 | Reduce 84.20% | 11,123 | $88.29 |
| Q4 2017 | -211,238 | Reduce 75.01% | 70,384 | $98.67 |
| Q3 2017 | -37,298 | Reduce 11.70% | 281,622 | $96.26 |
| Q2 2017 | -279,239 | Reduce 46.68% | 318,920 | $94.52 |
| Q1 2017 | +33,320 | Add 5.90% | 598,159 | $81.61 |
| Q4 2016 | +118,963 | Add 26.68% | 564,839 | $84.83 |
| Q3 2016 | +229,329 | Add 105.90% | 445,876 | $74.50 |
| Q2 2016 | +62,890 | Add 40.93% | 216,547 | $75.88 |
| Q1 2016 | +77,333 | Add 101.32% | 153,657 | $69.32 |
| Q4 2015 | +66,619 | Add 686.44% | 76,324 | $60.22 |
| Q3 2015 | +5,928 | Add 156.95% | 9,705 | $54.10 |
| Q2 2015 | -312 | Reduce 7.63% | 3,777 | $57.98 |
| Q1 2015 | -23 | Reduce 0.56% | 4,089 | $60.16 |
| Q4 2014 | +4,112 | New Buy | 4,112 | $53.26 |
| Q3 2013 | -14,216 | Sold Out | 0 | $0.00 |
| Q2 2013 | +14,216 | Add 0.00% | 14,216 | $35.10 |
| Q4 2012 | +24,556 | Add 0.00% | 24,556 | $27.37 |
Cliff Asness's West Pharmaceutical Services Investment FAQs
Cliff Asness first purchased West Pharmaceutical Services, Inc. (WST) in Q4 2012, acquiring 24,556 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held West Pharmaceutical Services, Inc. (WST) for 49 quarters since Q4 2012.
Cliff Asness's largest addition to West Pharmaceutical Services, Inc. (WST) was in Q3 2025, adding 545,879 shares worth $142.95 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 517,631 shares of West Pharmaceutical Services, Inc. (WST), valued at approximately $142.42 M.
As of the Q4 2025 filing, West Pharmaceutical Services, Inc. (WST) represents approximately 0.07% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in West Pharmaceutical Services, Inc. (WST) was 598,159 shares, as reported at the end of Q1 2017.